v3.26.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Treasury Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Balance at beginning of period at Dec. 31, 2024 $ 1,121,637   $ 839 $ (574,856) $ 752,371 $ 18,683 $ 924,600
Balance at beginning of period, shares at Dec. 31, 2024     83,948,000        
Balance at beginning of period, shares at Dec. 31, 2024       (20,295,000)      
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock 96       96    
Issuance of common stock, shares     1,000        
Shares withheld related to net settlement of equity awards (9,195)     $ (9,195)      
Shares withheld related to net settlement of equity awards, shares       (156,000)      
Vesting of restricted share grants, shares     384,000        
Vesting of restricted share grants     $ 4   (4)    
Exercise of options, shares     43,000        
Exercise of options 453   $ 1   452    
Other comprehensive loss (2,976)         (2,976)  
Share-based compensation 3,505       3,505    
Dividends paid (30,929)           (30,929)
Net Income (Loss) 61,975           61,975
Balance at end of period at Mar. 31, 2025 1,144,566   $ 844 $ (584,051) 756,420 15,707 955,646
Balance at end of period, shares at Mar. 31, 2025     84,376,000        
Balance at end of period, shares at Mar. 31, 2025       (20,451,000)      
Balance at beginning of period at Dec. 31, 2024 1,121,637   $ 839 $ (574,856) 752,371 18,683 924,600
Balance at beginning of period, shares at Dec. 31, 2024     83,948,000        
Balance at beginning of period, shares at Dec. 31, 2024       (20,295,000)      
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss (5,904)         (5,904)  
Net Income (Loss) 120,709            
Balance at end of period at Jun. 30, 2025 2,465,125 $ 197 $ 877 $ (607,244) 2,086,837 12,779 971,679
Balance at end of period, shares at Jun. 30, 2025   19,742,000 87,749,000        
Balance at end of period, shares at Jun. 30, 2025       (20,823,000)      
Balance at beginning of period at Mar. 31, 2025 1,144,566   $ 844 $ (584,051) 756,420 15,707 955,646
Balance at beginning of period, shares at Mar. 31, 2025     84,376,000        
Balance at beginning of period, shares at Mar. 31, 2025       (20,451,000)      
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock 424       424    
Issuance of common stock, shares     2,000        
Repurchase of shares (21,376)     $ (21,376)      
Repurchase of shares, shares       (342,000)      
Repurchased shares pending settlement (4,181)       (4,181)    
Shares withheld related to net settlement of equity awards (1,817)     $ (1,817)      
Shares withheld related to net settlement of equity awards, shares       (30,000)      
Vesting of restricted share grants, shares     29,000        
Exercise of options, shares     49,000        
Exercise of options 407       407    
Other comprehensive loss (2,928)         (2,928)  
Share-based compensation 5,658       5,658    
Issuance of stock in connection with the acquisition of Amundi US 1,328,339 $ 197 $ 33   1,328,109    
Issuance of stock in connection with the acquisition of Amundi US, shares   19,742,000 3,293,000        
Dividends paid (42,701)           (42,701)
Net Income (Loss) 58,734           58,734
Balance at end of period at Jun. 30, 2025 2,465,125 $ 197 $ 877 $ (607,244) 2,086,837 12,779 971,679
Balance at end of period, shares at Jun. 30, 2025   19,742,000 87,749,000        
Balance at end of period, shares at Jun. 30, 2025       (20,823,000)      
Balance at beginning of period at Dec. 31, 2025 $ 2,424,729 $ 199 $ 879 $ (786,008) 2,102,938 9,020 1,097,701
Balance at beginning of period, shares at Dec. 31, 2025   19,937,000 87,867,000        
Balance at beginning of period, shares at Dec. 31, 2025 23,717,000     (23,717,000)      
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock $ 157       157    
Issuance of common stock, shares     1,000        
Repurchase of shares (128,303)     $ (128,303)      
Repurchase of shares, shares       (1,796,000)      
Shares withheld related to net settlement of equity awards (16,045)     $ (16,045)      
Shares withheld related to net settlement of equity awards, shares       (232,000)      
Vesting of restricted share grants, shares     328,000        
Vesting of restricted share grants     $ 3   (3)    
Exercise of options, shares     193,000        
Exercise of options 1,690   $ 2   1,688    
Other comprehensive loss (378)         (378)  
Share-based compensation 7,412       7,412    
Conversion of common stock to preferred stock, shares [1]   100,000   (100,000)      
Conversion of common stock to preferred stock [1]   $ 1     (1)    
Dividends paid (41,565)           (41,565)
Net Income (Loss) 112,140           112,140
Balance at end of period at Mar. 31, 2026 2,359,837 $ 200 $ 884 $ (930,356) 2,112,191 8,642 1,168,276
Balance at end of period, shares at Mar. 31, 2026   20,037,000 88,389,000        
Balance at end of period, shares at Mar. 31, 2026       (25,845,000)      
Balance at beginning of period at Dec. 31, 2025 $ 2,424,729 $ 199 $ 879 $ (786,008) 2,102,938 9,020 1,097,701
Balance at beginning of period, shares at Dec. 31, 2025   19,937,000 87,867,000        
Balance at beginning of period, shares at Dec. 31, 2025 23,717,000     (23,717,000)      
Increase (Decrease) in Stockholders' Equity              
Other comprehensive loss $ (1,987)         (1,987)  
Net Income (Loss) 251,544            
Balance at end of period at Jun. 30, 2026 $ 2,375,062 $ 200 $ 886 $ (1,028,046) 2,128,399 7,033 1,266,590
Balance at end of period, shares at Jun. 30, 2026   20,037,000 88,554,000        
Balance at end of period, shares at Jun. 30, 2026 26,993,000     (26,993,000)      
Balance at beginning of period at Mar. 31, 2026 $ 2,359,837 $ 200 $ 884 $ (930,356) 2,112,191 8,642 1,168,276
Balance at beginning of period, shares at Mar. 31, 2026   20,037,000 88,389,000        
Balance at beginning of period, shares at Mar. 31, 2026       (25,845,000)      
Increase (Decrease) in Stockholders' Equity              
Issuance of common stock 70       70    
Issuance of common stock, shares     1,000        
Repurchase of shares (92,297)     $ (92,297)      
Repurchase of shares, shares       (1,079,000)      
Shares withheld related to net settlement of equity awards (5,393)     $ (5,393)      
Shares withheld related to net settlement of equity awards, shares       (69,000)      
Vesting of restricted share grants, shares     119,000        
Vesting of restricted share grants     $ 1   (1)    
Exercise of options, shares     45,000        
Exercise of options 364   $ 1   363    
Other comprehensive loss (1,609)         (1,609)  
Share-based compensation 15,776       15,776    
Dividends paid (41,090)           (41,090)
Net Income (Loss) 139,404           139,404
Balance at end of period at Jun. 30, 2026 $ 2,375,062 $ 200 $ 886 $ (1,028,046) $ 2,128,399 $ 7,033 $ 1,266,590
Balance at end of period, shares at Jun. 30, 2026   20,037,000 88,554,000        
Balance at end of period, shares at Jun. 30, 2026 26,993,000     (26,993,000)      
[1] Pursuant to the terms set forth in the Shareholder Agreement, the Company issued to Amundi shares of Preferred stock in exchange for an equal number of shares of Common stock.